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On 19 September 2012, Food and Chemical Toxicology
published online an article by Séralini et al. that reports the results
of a 2-year feeding study in rats investigating the health effects of
genetically modiﬁed maize NK603 with and without Roundup
WeatherMAX and Roundup GT Plus alone.
This article attracted great attention within the scientiﬁc and
regulatory community. Substantial gaps in the study design,
fundamental ﬂaws in the data analysis and erroneous interpreta-
tion of results have been pointed out by individual scientists and
administration bodies. Upon request by the European Commission,
the European Food and Safety Authority (EFSA) reviewed the study
and concluded that the design, reporting and analysis of the study
as presented in Food and Chemical Toxicology are inadequate and
that this contribution is of insufﬁcient scientiﬁc quality to be rele-
vant in the safety assessment process (http://www.efsa.europa.eu/
en/press/news/121004.htm).
The European Society of Toxicologic Pathology (ESTP) also
reviewed this article. ESTP members are pathologists specialized
in the diagnosis and interpretation of animal pathology from safety
studies, particularly rodent carcinogenesis bioassays. Since gener-
ation and interpretation of pathology data are of paramount
importance in carcinogenicity studies, the ESTP wants to highlight
major pathology shortcomings in the article by Séralini et al.
First it needs to be pointed out that a conclusion of such an
experimental study cannot be drawn without a good knowledge
of spontaneous pathology and the availability of a robust set of
internal historical pathology control data (Keenan et al., 2009).
These data are especially mandatory for a proper review of this
study as a limited number of control animals was included (Roe
et al., 1995; Deschl et al., 2002; Dinse et al., 2010). The absence
of documented knowledge of background lesions can lead to false
interpretations. For instance, this is clearly the case for the Wilm’s
tumors reported in the study. Nephroblastomas (the internation-
ally agreed term for this tumor entity in rodents) are well known
spontaneous neoplasms in rats that occur very early in life (Mesﬁn,
1999; Seely, 2004; Maxie, 2007; Frazier et al., 2012). They often
lead to a premature death of the animal, and in such cases the
cause of death is the speciﬁc tumor and not a treatment effect.
Here the comparison for the time of onset between control and
treated groups is not relevant as the comparison does not apply
to the same tumor type (Son et al., 2010).
The second point we would like to address is the use of atypical
concepts regarding the pathology results and their presentation,
for example the failure to provide tables of incidence of neoplastic
data. In the paper, it is stated that not all data can be shown in one0278-6915  2012 Published by Elsevier Ltd.
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There is only one table (Table 2) in which, unfortunately, the pre-
sentation of proliferative and non-proliferative lesions is inaccu-
rate and confusing as the data are pooled. The decision to
combine galactoceles, ﬁbroadenomas and adenocarcinoma in the
mammary gland has no scientiﬁc or regulatory justiﬁcation. Those
entities are completely different from each other with varied
causes and have therefore to be analyzed separately. Knowing that
mammary gland ﬁbroadenomas are very frequent in female rats
and especially in the Sprague–Dawley strain, the comparison with
background incidence of each tumor type would have been more
powerful to demonstrate a real treatment-related effect (Dince
et al., 2010). The sentence ‘‘The largest palpable growths (. . .) were
found to be in 95% of cases non-regressive tumors, and were not infec-
tious nodules.’’ is very confusing. We hope that differentiating
inﬂammatory from neoplastic lesions was not a challenge for the
authors. Another clear example illustrating the lack of accuracy
of the results is found in Fig. 3 where microscopic necrotic foci
in the liver are grouped with clear-cell focus and basophilic focus
with atypia. The ﬁrst ﬁnding refers to a degenerative process
whereas the remaining two refer to a proliferative one (Thoolen
et al., 2010). Such basic error would be considered as a disqualify-
ing mistake at an examination for pathologists. Later the tumors
are said to increase in size and number but not proportionally to
the treatment dose over treatment. The clinical progression of a
cancer depends on the tumor type and on its biological features,
but not on the dose of treatment. The presentation of chronic pro-
gressive nephropathy is inadequate: the severity should be also
displayed along with the incidence for a complete understanding
of a treatment-related exacerbation of this lesion (Hard and Khan,
2004). Additionally, there was erroneous interpretation of normal
ultrastructural images from this carcinogenesis study: The de-
scribed increased endoplasmic reticulum is the consequence of a
hepatic enzyme induction by the treatment (Cheville Norman,
1994). It has to be considered as an adaptative effect and not as
an adverse effect (Capen, 2001 – in Casarett & Doull’s book).
The third point which we wish to highlight is the absence of ref-
erence to good practices in toxicologic pathology. A pathologist
must always be responsible for the generation of histopathology
data and their interpretation in these study types. He must sign
to accredit this expertise. Why is the scientist responsible for the
pathology assessment in the study (i.e. the Study Pathologist)
not identiﬁed in the list of contributors of this work? Has there
been a formal or informal Peer Review of the histopathological
evaluation of the study? These practices are standard require-
ments for the evaluation of any carcinogenicity study (Crissman
et al., 2004).
Last but not least wewould like to comment on animal welfare is-
sues. As most members of the ESTP are veterinarians, we were
shockedby the photographs ofwhole bodyanimals bearing very large
tumors.When looking at the lesions, we believe those animals should
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islation on laboratory animal protection (http://eur-lex.europa.eu/
LexUriServ/LexUriServ.do?uri = OJ:L:2010:276:0033:0079:EN:PDF).
The authors illustrate only that Sprague–Dawley rats develop mam-
mary tumors associated with pituitary tumors. Both mammary and
pituitary tumors are common background lesions in the
Sprague–Dawley rat strain after 2 years (Dinse et al., 2010). But we
clearly question the care brought to laboratory animals in this study
which is closely associated to the quality of the produced data.
The ESTP comes to the conclusion that the pathology data pre-
sented in this paper are questionable and not correctly interpreted
and displayed because they don’t concur with the established pro-
tocols for interpreting rodent carcinogenicity studies and their rel-
evance for human risk assessment. The pathology description and
conclusion of this study are unprofessional. There are misinterpre-
tations of tumors and related biological processes, misuse of diag-
nostic terminology; pictures are not informative and presented
changes do not correspond to the narrative. We would like to ﬁnish
our commentary with a question: what is the scientiﬁc rationale
that led the journal reviewers and the editorial board of Food
and Chemical Toxicology to accept this article for publication?
This letter presents the scientiﬁc opinion of the ESTP members rep-
resented by its Executive Committee and colleagues who did the
review.
Frédéric Schorsch (Chairman of the ESTP Executive Committee)
Roger Alison
Sibylle Gröters
Rudolf Müller
Anna Lanzoni
Thomas Nolte
Jenny McKay (ESTP Designated Chairman)
Matthias Rinke
Annette Romeike (ESTP Past Chairman).
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